The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double‐Blind, Placebo‐Controlled Study
Open accessAbstract
Objective.—To assess the efficacy and safety of botulinum toxin type A (BoNT‐A; BOTOX ® , Allergan, Inc., Irvine, CA) for the prophylaxis of headaches in patients with chronic daily headache (CDH) without the confounding factor of concurrent prophylactic medications. Background.—Several open‐label studies and an 11‐month, randomized, double‐blind, placebo‐controlled study suggest that BoNT‐A may be an effective therapy for the prophylaxis of headaches in patients with CDH. Design and Methods.—This was a subgroup analysis of an 11‐month, randomized double‐blind, placebo‐controlled study of BoNT‐A for the treatment of adult patients with 16 or more headache days per 30‐day periods conducted at 13 North American study centers. All patients had a history of migraine or probable migraine. This analysis involved data for patients who were not receiving concomitant prophylactic headache medication and who constituted 64% of the full study population. Following a 30‐day screening period and a 30‐day single‐blind, placebo injection, eligible patients were injected with BoNT‐A or placebo and assessed every 30 days for 9 months The following efficacy measures were analyzed per 30‐day periods: change from baseline in number of headache‐free days; change from baseline in headache frequency; proportion of patients with at least 30% or at least 50% decrease from baseline in headache frequency; and change from baseline in mean headache severity. Acute medication use was assessed, and adverse events were recorded at each study visit. Results.—Of the 355 patients randomized in the study, 228 (64%) were not taking prophylactic medication and were included in this analysis (117 received BoNT‐A, 111 received placebo injections). Mean age was 42.4 ± 10.90 years; the mean frequency of headaches per 30 days at baseline was 14.1 for the BoNT‐A group and 12.9 for the placebo group ( P = .205). After two injection sessions, the maximum change in the mean frequency of headaches per 30 days was −7.8 in the BoNT‐A group compared with only −4.5 in the placebo group ( P = .032), a statistically significant between‐group difference of 3.3 headaches. The between‐group difference favoring BoNT‐A treatment continued to improve to 4.2 headaches after a third injection session ( P = .023). In addition, BoNT‐A treatment at least halved the frequency of baseline headaches in over 50% of patients after three injection sessions compared to baseline. Statistically significant differences between BoNT‐A and placebo were evident for the change from baseline in headache frequency and headache severity for most time points from day 180 through day 270. Only 5 patients (4 patients receiving BoNT‐A treatment; 1 patient receiving placebo) discontinued the study due to adverse events and most treatment‐related events were transient and mild to moderate in severity. Conclusions.—BoNT‐A is an effective and well‐tolerated prophylactic treatment in migraine patients with CDH who are not using other prophylactic medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II
Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2001.041007646.x · Cited by 2,268
Topiramate in the Treatment of Chronic Migraine
Silvestrini, M., Bartolini, M., Coccia, M., Baruffaldi, R., Taffi, R., & Provinciali, L. (2003) · Cephalalgia · doi:10.1046/j.1468-2982.2003.00592.x · Cited by 162
Cited by
Aurora, S., Dodick, D., Turkel, C., DeGryse, R., Silberstein, S., Lipton, R., Diener, H., & Brin, M. (2010) · Cephalalgia · doi:10.1177/0333102410364676 · Cited by 1,047
Self-citationDodick, D. W., Turkel, C. C., DeGryse, R. E., Aurora, S. K., Silberstein, S. D., Lipton, R. B., Diener, H., & Brin, M. F. (2010) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2010.01678.x · Cited by 994
Self-citationDiener, H., Dodick, D., Aurora, S., Turkel, C., DeGryse, R., Lipton, R., Silberstein, S., & Brin, M. (2010) · Cephalalgia · doi:10.1177/0333102410364677 · Cited by 960
Self-citationEFNS guideline on the drug treatment of migraine—revised report of an EFNS task force
Evers, S., Áfra, J., Frese, A., Goadsby, P. J., Linde, M., May, A., & Sándor, P. S. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02748.x · Cited by 892
Diener, H.-C., Kronfeld, K., Boewing, G., Lungenhausen, M., Maier, C., Molsberger, A., Tegenthoff, M., Trampisch, H.-J., Zenz, M., & Meinert, R. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70382-9 · Cited by 419
Metadata
- Authors
- Dodick, D. W., Mauskop, A., Elkind, A. H., DeGryse, R., Brin, M. F., Silberstein, S. D., & BOTOX CDH Study Group
- Venue
- Headache: The Journal of Head and Face Pain
- Publisher
- Wiley
- Published
- 2005-04
- Volume
- 45
- Issue
- 4
- Pages
- 315-324
- ISSN
- 0017-8748 (ISSN-L)
- 1526-4610
- OpenAlex
- W1967849656
- Cited by
- 221
- References
- 2
- FWCI
- 16.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double‐Blind, Placebo‐Controlled Study. https://app.cochat.ai/papers/10.1111/j.1526-4610.2005.05068.x
- The paper
- Dodick, D. W., Mauskop, A., Elkind, A. H., DeGryse, R., Brin, M. F., Silberstein, S. D., & BOTOX CDH Study Group. (2005). Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double‐Blind, Placebo‐Controlled Study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2005.05068.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.